RESEARCH TRIANGLE PARK, N.C., and LOS ANGELES, Sept. 18 /PRNewswire/ -- Amphora Discovery announced today that CHDI, Inc., a non-profit organization pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow Huntington Disease (HD) has signed multiple agreements that provide access to Amphora Discovery's integrated contract discovery services. HD is an inherited degenerative brain disease for which there is currently no treatment to delay or prevent its onset. CHDI partners with leading industrial and academic institutions to discover novel therapies for HD and will utilize Amphora Discovery's services and expertise in drug discovery to further this mission.
